Ret Fusion-positive Solid Tumors

• FDA approval · 2025-11-20
  FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)

  The FDA approved a supplemental application for RETEVMO (selpercatinib) submitted by Eli Lilly and Company, expanding its approved indicatio…

• CLINICAL_TRIALS trial_result · 2022-06-02
  Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation [Phase 2]

  Phase 2 study of selpercatinib (Retevmo) in adults with advanced RET-altered solid tumors, including RET fusion–positive cancers and medulla…